Royalty Pharma acquires and manages royalty interests in biopharmaceutical products, providing capital to innovators in exchange for a share of future sales. Its portfolio spans marketed drugs and development-stage assets across multiple therapeutic areas. The model offers exposure to drug cash flows without operating manufacturing or commercial sales forces.
| Quarter | Revenue | YoY % | Earnings | YoY % |
|---|---|---|---|---|
| Q2 2025 | 578.7 | — | 32.2 | — |
| Q3 2025 | 609.3 | — | 288.2 | — |
| Q4 2025 | 622 | — | 214.2 | — |
| Q1 2026 | 630.6 | — | 294.7 | — |
| Q2 2026 | 674.1 | 16.5% | 17.9 | -44.4% |
All markets — KeepWinning global stock screener
Other companies on Nasdaq: Kimberly-Clark Corporation (KMB), Expedia Group, Inc. (EXPE), Arch Capital Group Ltd. (ACGL), Steel Dynamics, Inc. (STLD), Biogen Inc. (BIIB), Telefonaktiebolaget LM Ericsson (publ) (ERIC)